UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...
GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback